Switchability of Gabapentin Formulations: A Randomized Trial to Assess Bioequivalence Between Neurontin and Gabasandoz on the Individual Subject Level-Reference-Cited by-同舟云学术

Switchability of Gabapentin Formulations: A Randomized Trial to Assess Bioequivalence Between Neurontin and Gabasandoz on the Individual Subject Level

Published:2019-03-02 Issue:1 Volume:106 Page:195-203
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Van Lancker Griet¹²^ORCID,Van Bortel Luc¹²,Delafontaine Brant¹²^ORCID,Boussery Koen³⁴^ORCID,Swart Eleonora⁵^ORCID,Chahbouni Abdel⁵,Van Bocxlaer Jan³^ORCID,Colin Pieter³⁶^ORCID

Affiliation:

1. Heymans Institute of PharmacologyGhent University Ghent Belgium

2. Drug Research Unit GhentGhent University Hospital Ghent Belgium

3. Laboratory of Medical Biochemistry and Clinical AnalysisFaculty of Pharmaceutical SciencesGhent University Ghent Belgium

4. Pharmaceutical Care UnitFaculty of Pharmaceutical SciencesGhent University Ghent Belgium

5. Department of Clinical Pharmacology and PharmacyVU University Medical Center Amsterdam The Netherlands

6. Department of AnesthesiaUniversity Medical Center GroningenGroningen University Groningen The Netherlands

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.1353

Reference24 articles.

1. US Food and Drug Administration (FDA).Guidance for industry: statistical approaches to establishing bioequivalence. (2001). Accessed August 2017.

2. Generic substitution in the treatment of epilepsy: Patient and physician perceptions

3. Generic substitution in the treatment of epilepsy: Case evidence of breakthrough seizures

4. The risks and costs of multiple-generic substitution of topiramate

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Within-subject pharmacokinetic variability has a strong influence on individual exposure ratios in bioequivalence studies, hence on drug formulation interchangeability;European Journal of Clinical Pharmacology;2023-09-22

2. Potentiel Impact thérapeutique de la substitution en cours de traitement d’un princeps par un générique : limites de la bioéquivalence moyenne pour les médicaments à marge thérapeutique étroite;Bulletin de l'Académie Nationale de Médecine;2023-04

3. Response to Comment on “Interchangeability Between Generic and Reference Products: Limits of Average Bioequivalence Methodology”;European Journal of Drug Metabolism and Pharmacokinetics;2023-01-21

4. Recommendations for treatment strategies in people with epilepsy during times of shortage of antiseizure medications;Epileptic Disorders;2022-10-01

5. Interchangeability between Generic and Reference Products: Limits of Average Bioequivalence Methodology;European Journal of Drug Metabolism and Pharmacokinetics;2022-08-19